CEO and CFO buying at Sirona Biochem (V:SBM)

Howard Jarman Verrico, CEO and Director, acquired 960,000 Common Shares on a direct ownership basis at a price of $0.100 through a prospectus or prospectus exempt offering on February 27th, 2019. The insider also acquired 960,000 Warrants with an exercise price of $0.160 for 3 years. This represents a $96,000 investment into the company's shares and an account share holdings change of 15.4%.

In addition, Christopher Hopton, CFO and Director, acquired 350,000 Common Shares and 350,000 Warrants on a direct ownership basis. This represents a $35,000 investment into the company's shares and an account share holdings change of 46.1%.

Sirona Biochem is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Sirona Biochem Corp. is a Canada-based development-stage cosmetic ingredient and drug discovery company with a technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. It is engaged in the development of cosmetic and pharmaceutical active ingredients, which are licensed to its partners. The Company has six product lines: SGLT2 Inhibitor, Skin Lightener I, GlycoProteMin-Anti aging, Anti-inflammatory, Anti-infective and Skin Lightener II. Its development is focused on three programs: therapeutics, which includes diabetes, anti-inflammatories and anti-infectives; cosmeceuticals, which includes anti-aging and depigmenting agents (skin lighteners), and biological ingredients, which includes inducers and adjuvants for biological development and preservation. The Company, through TFChem S.A.R.L. (TFC), is engaged in using fluorine atom properties to develop glycomimetic compounds.